Publication at Faculty of Medicine in Hradec Králové |
2023
Abstract
Patients suffering from cholangiocarcinoma have very unfavorable prognosis, 5 years survival is usually less than 10 %. Progress in molecular testing of this tumors revealed better possibilities of targeted therapy.
One of the most represented changes is isocitrate dehydrogenase-1 (IDH-1) mutation. Selective inhibitor of mutated IDH-1 enzyme ivosidenib (Tibsovo(R)) is effective choice of treatment of this disease.